{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:05:21Z","timestamp":1793505921031,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00415-025-13266-y","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T04:00:34Z","timestamp":1755316834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial"],"prefix":"10.1007","volume":"272","clinical-trial-number":[{"clinical-trial-number":"nct02782741","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Priya S.","family":"Kishnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"D\u00edaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Illarioshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Kushlaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafeeq","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"Erdem-\u00d6zdamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina An","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huynh-Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Tammireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Periquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the COMET Investigator Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"13266_CR1","unstructured":"Reuser AJJ, Hirschhorn R, Kroos MA (2018) Pompe disease: glycogen storage disease type II, acid \u03b1-glucosidase (acid maltase) deficiency. In: Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, Mitchell G (eds) The online metabolic and molecular bases of inherited disease. The McGraw-Hill Companies, Inc., New York, NY"},{"key":"13266_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372:1342\u20131353","journal-title":"Lancet"},{"key":"13266_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ajmg.a.35662","volume":"161A","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Reuser AJ (2013) How to describe the clinical spectrum in Pompe disease? Am J Med Genet A 161A:399\u2013400. https:\/\/doi.org\/10.1002\/ajmg.a.35662","journal-title":"Am J Med Genet A"},{"key":"13266_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, Van der Ploeg AT (2005) Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients. Brain 128:671\u2013677. https:\/\/doi.org\/10.1093\/brain\/awh384","journal-title":"Brain"},{"key":"13266_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.c.31324","volume":"160C","author":"PS Kishnani","year":"2012","unstructured":"Kishnani PS, Beckemeyer AA, Mendelsohn NJ (2012) The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet 160C:1\u20137. https:\/\/doi.org\/10.1002\/ajmg.c.31324","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"13266_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.21037\/atm.2019.07.24","volume":"7","author":"A Toscano","year":"2019","unstructured":"Toscano A, Rodolico C, Musumeci O (2019) Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med 7:284. https:\/\/doi.org\/10.21037\/atm.2019.07.24","journal-title":"Ann Transl Med"},{"key":"13266_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ymgme.2022.01.003","volume":"135","author":"E Huggins","year":"2022","unstructured":"Huggins E, Holland M, Case LE, Blount J, Landstrom AP, Jones HN, Kishnani PS (2022) Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening. Mol Genet Metab 135:179\u2013185. https:\/\/doi.org\/10.1016\/j.ymgme.2022.01.003","journal-title":"Mol Genet Metab"},{"key":"13266_CR8","unstructured":"Genzyme (2022) LUMIZYME\u00ae (alglucosidase alfa) for injection, for intravenous use. [Prescribing Information]. Genzyme Corporation, Cambridge, MA"},{"key":"13266_CR9","unstructured":"Genzyme (2019) MYOZYME\u00ae (alglucosidase alfa) Injectable for intravenous infusion. [Prescribing Information]. Genzyme Corporation, Cambridge, MA"},{"key":"13266_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","volume":"166","author":"YH Chien","year":"2015","unstructured":"Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, Huang HJ, Hsu WC, Tsai TH, Hwu WL (2015) Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr 166:985-991 e982. https:\/\/doi.org\/10.1016\/j.jpeds.2014.10.068","journal-title":"J Pediatr"},{"key":"13266_CR11","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","volume":"268","author":"K Gutschmidt","year":"2021","unstructured":"Gutschmidt K, Musumeci O, Diaz-Manera J, Chien YH, Knop KC, Wenninger S, Montagnese F, Pugliese A, Tavilla G, Alonso-Perez J, Hwu PW, Toscano A, Schoser B (2021) STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa. J Neurol 268:2482\u20132492. https:\/\/doi.org\/10.1007\/s00415-021-10409-9","journal-title":"J Neurol"},{"key":"13266_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/atm.2019.04.70","volume":"7","author":"A Hahn","year":"2019","unstructured":"Hahn A, Schanzer A (2019) Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med 7:283. https:\/\/doi.org\/10.21037\/atm.2019.04.70","journal-title":"Ann Transl Med"},{"key":"13266_CR13","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel JY, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, Canal A, Brusse E, van Doorn PA, van der Ploeg AT, Laforet P, van der Beek N (2019) Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology 93:e1756\u2013e1767. https:\/\/doi.org\/10.1212\/WNL.0000000000008441","journal-title":"Neurology"},{"key":"13266_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26\u201333. https:\/\/doi.org\/10.1016\/j.ymgme.2009.08.003","journal-title":"Mol Genet Metab"},{"key":"13266_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1750-1172-8-90","volume":"8","author":"SN Prater","year":"2013","unstructured":"Prater SN, Patel TT, Buckley AF, Mandel H, Vlodavski E, Banugaria SG, Feeney EJ, Raben N, Kishnani PS (2013) Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis 8:90. https:\/\/doi.org\/10.1186\/1750-1172-8-90","journal-title":"Orphanet J Rare Dis"},{"key":"13266_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jimd.12272","volume":"43","author":"C Semplicini","year":"2020","unstructured":"Semplicini C, De Antonio M, Taouagh N, B\u00e9hin A, Bouhour F, Echaniz-Laguna A, Magot A, Nadaj-Pakleza A, Orlikowski D, Sacconi S, Salort-Campana E, Sol\u00e9 G, Tard C, Zagnoli F, Hogrel JY, Hamroun D, Laforet P, French Pompe Study Group (2020) Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry. J Inherit Metab Dis 43:1219\u20131231. https:\/\/doi.org\/10.1002\/jimd.12272","journal-title":"J Inherit Metab Dis"},{"key":"13266_CR17","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1007\/s00415-024-12489-9","volume":"271","author":"KI Berger","year":"2024","unstructured":"Berger KI, Chien YH, Dubrovsky A, Kishnani PS, Llerena JC Jr, Neilan E, Roberts M, Sheng B, Batista JL, Periquet M, Wilson KM, van der Ploeg AT (2024) Changes in forced vital capacity over <\/= 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry. J Neurol 271:5433\u20135446. https:\/\/doi.org\/10.1007\/s00415-024-12489-9","journal-title":"J Neurol"},{"key":"13266_CR18","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1021\/bc400365a","volume":"24","author":"Q Zhou","year":"2013","unstructured":"Zhou Q, Avila LZ, Konowicz PA, Harrahy J, Finn P, Kim J, Reardon MR, Kyazike J, Brunyak E, Zheng X, Patten SM, Miller RJ, Pan CQ (2013) Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein. Bioconjug Chem 24:2025\u20132035. https:\/\/doi.org\/10.1021\/bc400365a","journal-title":"Bioconjug Chem"},{"key":"13266_CR19","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/mt.2009.37","volume":"17","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Jiang JL, Gumlaw NK, Zhang J, Bercury SD, Ziegler RJ, Lee K, Kudo M, Canfield WM, Edmunds T, Jiang C, Mattaliano RJ, Cheng SH (2009) Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 17:954\u2013963. https:\/\/doi.org\/10.1038\/mt.2009.37","journal-title":"Mol Ther"},{"key":"13266_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","volume":"1793","author":"T Braulke","year":"2009","unstructured":"Braulke T, Bonifacino JS (2009) Sorting of lysosomal proteins. Biochem Biophys Acta 1793:605\u2013614. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.10.016","journal-title":"Biochem Biophys Acta"},{"key":"13266_CR21","unstructured":"Genzyme (2021) NEXVIAZYME\u00ae (avalglucosidase alfa-ngpt) for injection, for intravenous use. [Prescribing Information]. Genzyme Corporation, Cambridge, MA"},{"key":"13266_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B, COMET Investigator Group (2021) Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol 20:1012\u20131026. https:\/\/doi.org\/10.1016\/S1474-4422(21)00241-6","journal-title":"Lancet Neurol"},{"key":"13266_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","volume":"80","author":"PS Kishnani","year":"2023","unstructured":"Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B, COMET Investigator Group (2023) Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial. JAMA Neurol 80:558\u2013567. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0552","journal-title":"JAMA Neurol"},{"key":"13266_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS\/ERS Task Force (2005) Standardisation of spirometry. Eur Respir J 26:319\u2013338. https:\/\/doi.org\/10.1183\/09031936.05.00034805","journal-title":"Eur Respir J"},{"key":"13266_CR25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J, Global Lung Function Initiative ERS (2012) Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324\u20131343. https:\/\/doi.org\/10.1183\/09031936.00080312","journal-title":"Eur Respir J"},{"key":"13266_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111\u2013117. https:\/\/doi.org\/10.1164\/ajrccm.166.1.at1102","journal-title":"Am J Respir Crit Care Med"},{"key":"13266_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00008483-200103000-00005","volume":"21","author":"WJ Gibbons","year":"2001","unstructured":"Gibbons WJ, Fruchter N, Sloan S, Levy RD (2001) Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 21:87\u201393. https:\/\/doi.org\/10.1097\/00008483-200103000-00005","journal-title":"J Cardiopulm Rehabil"},{"key":"13266_CR28","doi-asserted-by":"publisher","unstructured":"Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, Geiger H, Loeckinger A, Stein JI (2007) Six-minute walk test in children and adolescents. J Pediat 150:395\u2013399, 399 e391\u2013392. https:\/\/doi.org\/10.1016\/j.jpeds.2006.12.052","DOI":"10.1016\/j.jpeds.2006.12.052"},{"key":"13266_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/ptj\/76.3.248","volume":"76","author":"AW Andrews","year":"1996","unstructured":"Andrews AW, Thomas MW, Bohannon RW (1996) Normative values for isometric muscle force measurements obtained with hand-held dynamometers. Phys Ther 76:248\u2013259. https:\/\/doi.org\/10.1093\/ptj\/76.3.248","journal-title":"Phys Ther"},{"key":"13266_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","volume":"35","author":"CI van Capelle","year":"2012","unstructured":"van Capelle CI, van der Beek NA, de Vries JM, van Doorn PA, Duivenvoorden HJ, Leshner RT, Hagemans ML, van der Ploeg AT (2012) The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis 35:317\u2013323. https:\/\/doi.org\/10.1007\/s10545-011-9388-3","journal-title":"J Inherit Metab Dis"},{"key":"13266_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1469-8749.2008.03089.x","volume":"50","author":"RJ Palisano","year":"2008","unstructured":"Palisano RJ, Rosenbaum P, Bartlett D, Livingston MH (2008) Content validity of the expanded and revised Gross Motor Function Classification System. Dev Med Child Neurol 50:744\u2013750. https:\/\/doi.org\/10.1111\/j.1469-8749.2008.03089.x","journal-title":"Dev Med Child Neurol"},{"key":"13266_CR32","volume-title":"Gross motor function measure (GMFM-66 & GMFM-88) user\u2019s manual","author":"D Russell","year":"2002","unstructured":"Russell D, Rosenbaum P, Avery L, Lane M (2002) Gross motor function measure (GMFM-66 & GMFM-88) user\u2019s manual. Cambridge University Press"},{"key":"13266_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mus.23340","volume":"45","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S, Moggio M, Comi GP, Musumeci O, Pegoraro E, Tonin P, Filosto M, Servidei S, Morandi L, Crescimanno G, Marrosu G, Siciliano G, Mongini T, Toscano A, Italian Group on GSDII (2012) New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve 45:831\u2013834. https:\/\/doi.org\/10.1002\/mus.23340","journal-title":"Muscle Nerve"},{"key":"13266_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220\u2013233. https:\/\/doi.org\/10.1097\/00005650-199603000-00003","journal-title":"Med Care"},{"key":"13266_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"LDM Pena","year":"2019","unstructured":"Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforet P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT, NEO1 Investigator Group (2019) Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul Disord 29:167\u2013186. https:\/\/doi.org\/10.1016\/j.nmd.2018.12.004","journal-title":"Neuromuscul Disord"},{"key":"13266_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.695","author":"M Dimachkie","year":"2020","unstructured":"Dimachkie M, Barohn R, Byrne B, Goker-Alpan O, Kishnani P, Ladha S, Lafor\u00eat P, Mengel KE, Pena L, Sacconi S, Straub V, Trivedi J, Van Damme P, van der Ploeg AT, Vissing J, Young P, an Haack K, Fleurinck C, Johnson J, Liu K, Schoser B (2020) NEO1 and NEO-EXT studies: long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 55 years in late-onset Pompe disease patients. Neurology. https:\/\/doi.org\/10.1212\/WNL.94.15_supplement.695","journal-title":"Neurology"},{"key":"13266_CR37","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","volume":"268","author":"H Wisselaar","year":"1993","unstructured":"Wisselaar H, Kroos M, Hermans M, van Beeumen J, Reuser A (1993) Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268:2223\u20132231","journal-title":"J Biol Chem"},{"key":"13266_CR38","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s00415-019-09401-1","volume":"266","author":"KI Berger","year":"2019","unstructured":"Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A (2019) Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. J Neurol 266:2312\u20132321. https:\/\/doi.org\/10.1007\/s00415-019-09401-1","journal-title":"J Neurol"},{"key":"13266_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A (2017) Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 264:621\u2013630. https:\/\/doi.org\/10.1007\/s00415-016-8219-8","journal-title":"J Neurol"},{"key":"13266_CR40","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362:1396\u20131406","journal-title":"N Engl J Med"},{"key":"13266_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM de Vries","year":"2012","unstructured":"de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber CG, Verschuuren JJ, Kruijshaar ME, Reuser AJ, van Doorn PA, van der Ploeg AT (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73. https:\/\/doi.org\/10.1186\/1750-1172-7-73","journal-title":"Orphanet J Rare Dis"},{"key":"13266_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21037\/atm.2019.04.15","volume":"7","author":"HV Do","year":"2019","unstructured":"Do HV, Khanna R, Gotschall R (2019) Challenges in treating Pompe disease: an industry perspective. Ann Transl Med 7:291. https:\/\/doi.org\/10.21037\/atm.2019.04.15","journal-title":"Ann Transl Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13266-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:35:30Z","timestamp":1760524530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13266-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13266"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13266-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.S. Kishnani\u2014Consultant\/Advisory Board: Amicus Therapeutics, Asklepios Biopharmaceutical, Inc.), JCR Pharmaceuticals, Maze Therapeutics, and Sanofi. Grant\/Research Support: Amicus Therapeutics and Sanofi. Other Financial or Material Support: Amicus Therapeutics, Baebies, and Sanofi (Pompe and Gaucher Disease Registry); Asklepios Biopharmaceutical, Inc. (equity options); and Maze Therapeutics (equity which is developing a small molecule therapy for Pompe disease); J. D\u00edaz-Manera\u2014Consultant\/Advisory Board: Amicus, Audentes, Lupin, Sanofi, Sarepta, and Spark Therapeutics. Grant\/Research Support: Audentes, Boehringer Ingelheim, Sanofi, and Spark Therapeutics. Other Financial or Material Support: Boehringer Ingelheim (receipt of intellectual property rights\/patent holder); S. Illarioshkin\u2014Speakers Bureau\/Honoraria for non-CME: Ever Pharma, Merz Pharma, and Servier; A.T. van der Ploeg\u2014Consultant\/Advisory Board: Amicus, BioMarin, Sanofi, and Spark Therapeutics. Grant\/Research Support: Amicus, BioMarin, Sanofi, and Spark Therapeutics; P.R. Clemens\u2014Consultant\/Advisory Board: Epirium Bio, Pompe Registry North American Advisory Board, TRiNDS Catalyst Education and Med Learning Group. Grant\/Research Support: Amicus, NS Pharma, ReveraGen BioPharma, Sanofi, and Spark Therapeutics; J.W. Day\u2014Consultant\/Advisory Board: Affinia Therapeutics, AMO Pharma, Avidity Biosciences, Biogen, Cytokinetics, Epirium Bio, Ionis Pharmaceuticals, Kate Therapeutics, Novartis Gene Therapies, Roche\/Genentech Pharmaceuticals, Sarepta Therapeutics, Scholar Rock, Shift Therapeutics, Vertex Pharmaceuticals. Grant\/Research Support: AMO Pharma, Audentes, Astellas Gene Therapies, Avidity Biosciences, Biogen, Cure SMA, Cytokinetics, Genentech, Ionis Pharmaceuticals, Muscular Dystrophy Association, Novartis Gene Therapies, Roche Pharmaceuticals, Sanofi, Sarepta Therapeutics, Scholar Rock, SMA Foundation. Patent holder\/Royalties: Athena Diagnostics for Genetic Testing; A. Toscano\u2014Member of the European Reference Network for Neuromuscular Disorders (ERN-NMD)\u2014Project ID No 739543; H. Kushlaf\u2014Consultant\/Advisory Board: Argenx, Immunovant, Sanofi, Takeda, and UCB. Speakers Bureau\/Honoraria for non-CME: Akcea Therapeutics; S. Ladha\u2014Consultant\/Advisory Board: Sanofi. Grant\/Research Support: Sanofi. Speakers Bureau\/Honoraria for non-CME: Sanofi; S. Attarian\u2014Nothing to disclose; G. Carvalho\u2014Nothing to disclose; A. Kostera-Pruszczyk\u2014Consultant\/Advisory Board: Argenx, Biogen, Roche, and PTC Therapeutics. Grant\/Research Support: Biogen, Kedrion Biopharma, Sanofi, and Takeda. Speakers Bureau\/Honoraria for non-CME: Biogen, CSL Behring, Kedrion Biopharma, Novartis, PTC Therapeutics, Roche, Sanofi, and Takeda; S. Erdem-\u00d6zdamar\u2014Speakers Bureau\/Honoraria for non-CME: Sanofi; O. Goker-Alpan\u2014Consultant\/Advisory Board: AVROBIO, Chiesi, Prevail Therapeutics, Sanofi, and Takeda. Grant\/Research Support: 4D Molecular Therapeutics, Homology Medicines, and Spark Therapeutics; T. Mozaffar\u2014Consultant\/Advisory Board: Alexion Pharmaceuticals, Argenx, Astellas Gene Therapies, Avro Bio, Sanofi, Spark Therapeutics, and Maze Therapeutics; V. Straub\u2014Consultant\/Advisory Board: Sanofi. Grant\/Research Support: Astellas Gene Therapies and Sanofi. Speakers Bureau\/Honoraria for non-CME: Sanofi; M. Roberts\u2014Consultant\/Advisory Board: Amicus and Sanofi; K. An Haack\u2014Employee: Sanofi. Stock Ownership\/Stock Option: Sanofi; O. Huynh-Ba\u2014Employee: Sanofi. Stock Ownership\/Stock Option: Sanofi; S. Tammireddy\u2014Employee: Sanofi. Stock Ownership\/Stock Option: Sanofi; M. Periquet\u2014Former Employee: Sanofi (Sanofi employee at the time of manuscript preparation). Stock Ownership\/Stock Option: Sanofi; N. Thibault\u2014Employee: Sanofi. Stock Ownership\/Stock Option: Sanofi; T. Zhou\u2014Employee: Sanofi. Stock Ownership\/Stock Option: Sanofi; M.M. Dimachkie\u2014Consultant\/Advisory Board: Abata\/Third Rock, Abcuro, Amazentis, Argenx, Catalyst Pharmaceuticals, Cello, Covance\/Labcorp, CSL-Behring, EcoR1, Janssen Pharmaceuticals, Kezar Life Sciences, MDA, Momenta, NuFactor, Octapharma, Priovant, Ra Pharma\/UCB, Roivant Sciences Inc, Sanofi, Shire Takeda, Scholar Rock, Spark Therapeutics, UCB Biopharma. Grant\/Research Support: Alexion, Alnylam Pharmaceuticals, Amicus, BioMarin, Bristol-Myers Squibb, Catalyst Pharmaceuticals, Corbus Grifols, CSL Behring, FDA\/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar Life Sciences, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma\/UCB, Sanofi, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, UCB Biopharma\/Ra Pharma, Viromed\/Helixmith, and TMA. Patent Holder\/Royalties: Medlink and UpToDate; B. Schoser\u2014Consultant\/Advisory Board: Amicus, Argenx, Astellas, Maze, Sanofi, Pepgen, and Taysha; Grant\/Research Support: Amicus and Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"581"}}